Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan stimulants prior auth | Open…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy N/A

    Stimulants and Related Agents - Analeptics (prior authorization)

    Customize your policy alerts

    Sign up for all Geisinger Health Plan policy alerts

    Know when Geisinger Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and criteria for stimulant and related analeptic medications (examples: Provigil, Nuvigil, Sunosi, Wakix) for Geisinger Health Plan members; applies to prescribers requesting new or renewal coverage for these drugs.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyStimulants and Related Agents - Analeptics (prior authorization)
    Policy CodePolicy N/A
    Change TypeNo material changes in this revision
    Effective DateJan 6, 2025
    Next Review DateN/A
    Key ActionSubmit the completed prior authorization form with required clinical documentation (diagnosis and DX code, medication list, objective testing or CPAP adherence, and prescriber signature) via PromptPA or fax.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    PROVIGIL / NUVIGIL / SUNOSI / WAKIXRepresentative drugs
    1/6/2025Form effective
    >10Epworth threshold
    <8 minMSLT threshold

    Coverage Criteria Overview

    Initial therapy criteria

    Covered when ALL of the following are met for the indicated condition

    Indication selection

    • Narcolepsy: Diagnosis is consistent with current International Classification of Sleep Disorders criteria (e.g., MSLT, overnight PSG, hypocretin-1 concentration, clinical assessment).
    • Shift work sleep disorder: Diagnosis is consistent with current International Classification of Sleep Disorders criteria (e.g., shift work schedule, sleep log & actigraphy monitoring, other causes ruled out, clinical assessment).
    • OSAHS: Diagnosis is consistent with current International Classification of Sleep Disorders criteria AND either: tried and failed CPAP while adherent to treatment to resolve daytime sleepiness (document CPAP adherence) OR cannot use CPAP (reason documented) OR tried and failed an oral appliance to resolve daytime sleepiness. Objective support may include Epworth Sleepiness Scale >10 or MSLT <8 minutes.
    Policy Summary
    PayerGeisinger Health Plan
    PolicyStimulants and Related Agents - Analeptics (prior authorization)
    Policy CodePolicy N/A
    Change TypeNo material changes in this revision
    Effective DateJan 6, 2025
    Next Review DateN/A
    Key ActionSubmit the completed prior authorization form with required clinical documentation (diagnosis and DX code, medication list, objective testing or CPAP adherence, and prescriber signature) via PromptPA or fax.
    SourceLink
    On This Page
    Coverage Criteria OverviewInitial Therapy — Indication-specific RequirementsRenewal / Continuation RequirementsProvider Actions and Documentation RequirementsRequired Coding and Objective MeasuresObjective Testing and DefinitionsStep Therapy / Prior Trial RequirementsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Document CPAP adherence and reasons if CPAP cannot be used.

  1. MS-related fatigue: Patient is currently receiving treatment for multiple sclerosis OR document reason not receiving MS treatment.
  2. Non-preferred agent requirement: For a NON-PREFERRED analeptic: history of trial and failure of, or contraindication or intolerance to, preferred analeptic agents per the PDL must be documented.

    Refer to the PDL for preferred vs non-preferred agents.

  3. The form does not list blanket exclusions by name, but it implicitly requires documentation that meets diagnostic and treatment-trial expectations; requests lacking that documentation are not supported. Specifically, if the submission does not include evidence that the diagnosis is consistent with current International Classification of Sleep Disorders criteria (e.g., MSLT, overnight PSG, hypocretin‑1 concentration, clinical assessment) or, for OSAHS, documentation of CPAP trial and adherence or reason CPAP cannot be used, the request would be considered incomplete and may be denied.

    Although the form does not enumerate explicit non‑coverage scenarios, providers must supply the required objective testing and trial information to demonstrate medical necessity. For non‑preferred analeptics, the form requires documentation of a history of trial and failure, or a contraindication or intolerance to preferred agents. Similarly, failure to provide objective measures (for example, Epworth Sleepiness Scale >10 or MSLT <8 minutes for OSAHS) or CPAP adherence/trial data will leave the request unsupported.

    Initial Therapy — Indication-specific Requirements

    Initial therapy

    Initial request criteria by indication

    Initial Indications: Narcolepsy, shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome (OSAHS) — with CPAP adherence and failure or inability to use CPAP and/or oral appliance failure documented — or fatigue related to multiple sclerosis.

    Diagnosis must be consistent with current International Classification of Sleep Disorders criteria and supported by appropriate testing and documentation (e.g., MSLT, PSG, sleep logs, actigraphy).

    Renewal / Continuation Requirements

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required — use Geisinger form (effective 1/6/2025)

    Prior authorization is required for stimulants and related analeptics; use the Geisinger prior authorization form (form effective 1/6/2025) for new and renewal requests and submit required clinical documentation.

    Step Therapy

    Document prior trial/failure or contraindication for non-preferred agents

    For any request for a non-preferred analeptic, document a history of trial and failure of — or a documented contraindication or intolerance to — preferred analeptic agents listed on the PDL for the beneficiary's diagnosis; this requirement applies to both initial and renewal requests.

    • Refer to the Preferred Drug List at https://papdl.com/preferred-drug-list for which agents are preferred.
    Documentation Required

    Required submission materials — completed form and supporting documentation

    Submit the completed Geisinger prior authorization form with required clinical documentation including the diagnosis and DX code, a current complete medication list, documentation of trials/failures (e.g., CPAP adherence, objective sleep testing results), prescriber signature, and any other applicable sections completed.

    • Include diagnosis and required DX code (form field: DX code (required)).
    • Provide documentation of CPAP adherence or reason CPAP cannot be used, Epworth Sleepiness Scale or MSLT results when applicable.
    • Send via PromptPA (https://ghp.promptpa.com) or fax completed form and documentation to Geisinger Health Plan at 570-271-5610.
    Denial Risk

    Incomplete diagnostic documentation may trigger denial

    Failure to document a diagnosis consistent with current International Classification of Sleep Disorders criteria or to provide required objective testing (e.g., MSLT, PSG, actigraphy, sleep logs) or CPAP/adherence documentation for OSAHS may result in denial of the request.

    • For narcolepsy, shift work sleep disorder, and OSAHS, ensure documentation meets International Classification of Sleep Disorders criteria (examples listed on the form).
    • For OSAHS, include CPAP adherence documentation, objective measures (Epworth >10 or MSLT <8) or documented reason CPAP cannot be used.

    Required Coding and Objective Measures

    Required diagnosis code on formmixed
    DX code (required)Requester must provide the beneficiary diagnosis code
    inv-06: Epworth Sleepiness Scale
    Epworth Sleepiness Scale threshold>10
    Use contextObjective support for daytime sleepiness in OSAHS to document need for analeptic therapy
    Source document itemListed as a required measure under initial requests for OSAHS: 'Epworth Sleepiness Scale >10'
    inv-07: Multiple Sleep Latency Test
    Multiple Sleep Latency Test threshold<8 minutes
    Use contextObjective measure of daytime sleepiness in OSAHS and narcolepsy evaluation
    Source document itemListed as a required measure under initial requests for OSAHS: 'Multiple sleep latency test (MSLT) <8 minutes'

    Objective Testing and Definitions

    inv-13: Objective testing for sleep disorders
    Examples of objective testingMultiple sleep latency test (MSLT); overnight polysomnography (PSG); out-of-center sleep testing; hypocretin-1 concentration; sleep logs; actigraphy
    Role in policyObjective testing is required to support diagnoses per International Classification of Sleep Disorders criteria for narcolepsy, shift work sleep disorder, and OSAHS
    Document referenceSource lists MSLT, overnight PSG, out-of-center testing, and hypocretin-1 concentration as examples of diagnostic evidence

    Step Therapy / Prior Trial Requirements

    StepRequirementNotes
    1
    Required prior trial or documentation of contraindication/intolerance to preferred analeptic agents per the PDL
    For both initial and renewal requests when the drug is non‑preferred: provider must document history of trial and failure, or a contraindication or intolerance to preferred analeptic Stimulants and Related Agents (see the Geisinger PDL).

    Background

    Analeptic stimulants are utilized to manage excessive daytime sleepiness across several conditions, including narcolepsy, shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome (when CPAP/oral appliance has failed or cannot be used), and fatigue related to multiple sclerosis. The form requests objective testing and documentation (for example, MSLT, PSG, sleep logs, or other measures) and adherence or trial information to support that the medication is medically necessary.